Document is current
Any future updates will be listed below
-
Authors
Dugourd, Aurelien https://orcid.org/0000-0002-0714-028X
Kuppe, Christoph https://orcid.org/0000-0003-4597-9833
Sciacovelli, Marco https://orcid.org/0000-0003-2958-4292
Gjerga, Enio https://orcid.org/0000-0001-8042-0395
Gabor, Attila
Emdal, Kristina B.
Vieira, Vitor
Bekker‐Jensen, Dorte B.
Kranz, Jennifer
Bindels, Eric.M.J.
Costa, Ana S.H.
Sousa, Abel
Beltrao, Pedro https://orcid.org/0000-0002-2724-7703
Rocha, Miguel
Olsen, Jesper V. https://orcid.org/0000-0002-4747-4938
Frezza, Christian https://orcid.org/0000-0002-3293-7397
Kramann, Rafael https://orcid.org/0000-0003-4048-6351
Saez‐Rodriguez, Julio https://orcid.org/0000-0002-8552-8976
-
Funding
Funding for this research was provided by:
Medical Research Council (MC_UU_12022/6)
Novo Nordisk Fonden (NNF14CC0001)
Lundbeckfonden (R193‐2015‐243)
H2020 European Research Council (ERC‐StG 677448)
- License Information
-
More Information
Article History
Received: 19 May 2020
Revised: 18 December 2020
Accepted: 21 December 2020
First Online: 27 January 2021
Conflict of interest
: The authors declare that they have no conflict of interest. C.F. is a member of the scientific advisory board of Owlstone and scientific adviser of Istesso. JSR has received funding from GSK and expects to receive funding from Sanofi and consultant fees from Travere Therapeutics.
